Thus, targeting the synthesis or downstream signaling of tumor-derived omentin-1 could represent a novel therapeutic strategy in colorectal cancer, particularly in settings where systemic omentin suppression is absent [59]. The gene discussed is ITLN1; the disease is colorectal cancer.